Regulatory Strategy for Drug and Device Development. Why it must start on Day One.
In the fast-paced world of life sciences innovation, the drive to “get moving” can be irresistible. Teams dive into development, eager to demonstrate progress.
Yet the companies that succeed long-term are those that pause first to plan, align, and build a regulatory strategy that turns vision into value.
After supporting hundreds of programs through various global regulatory pathways, one truth stands out: Time invested upfront in strategy saves exponentially more time and money later.
Treating regulatory strategy as a roadmap, not a checkpoint, can save time, reduce costs, and increase the likelihood of approval.
How do we avoid destroying our company by making the wrong regulatory decisions in year one?
1. Start With the End in Mind
Target Product Profile (TPP): Blueprint for Regulatory Success
Every development program should begin with a clear view of success. The Target Product Profile (TPP) is your blueprint. More than a technical document, it’s a strategic compass that aligns scientific ambition with regulatory expectations, commercial reality, and patient need.
💡TARGET PRODUCT PROFILE (TPP):
A Target Product Profile (TPP) is a strategic, living document used in drug and medical device development to outline the desired characteristics of a product — including safety, efficacy, and dosage — to meet specific medical needs. In other words, it bridges the gap between R&D and commercialisation, ensuring that the final product is both viable and valuable to end users.
A well-defined TPP drives efficient decision-making go/no-go calls, study design, and communication with regulators and investors alike.
Without it, teams risk developing a product in search of a problem, rather than solving the right problem from the start. Furthermore, maintaining and updating the TPP throughout development keeps teams aligned and responsive to both scientific and regulatory insight.
2. Quality Is the Foundation, Not a Form
Embedding Quality Systems Early in Development
Quality isn’t a hurdle to clear, it’s the base every regulatory pathway stands on. Whether developing a medicine or a medical device, embedding quality early is non-negotiable.
Retrofitting systems such as GLP, GCP, GMP, ISO 13485, ISO 14971 later rarely works. We’ve seen companies lose 12–18 months correcting gaps that could have been prevented with early planning. Those delays are costly, avoidable, and often fatal to momentum.
A proactive quality mindset reduces the risk of clinical holds, manufacturing issues, or post-approval surprises
3. Medicines vs Devices: Know Your Route
Medicines vs Devices: Regulatory Pathways Explained
The regulatory processes for medicines differ significantly from those for devices.
- Medicines demand rigorous clinical evidence for efficacy and safety.
- Devices rely on a risk-based classification and safety and performance data.
Because classification dictates the applicable regulations, regulatory pathway and data requirements, product classifications can vary between markets. Understanding the classification for your product in all of your markets is critical.
Misclassification of your product can derail budgets, timelines, and investor confidence.
4. Lessons From the Field
Early Regulatory Strategy Development is Proven in Saving Time and Money
- We’ve seen startups bypass Phase II trials, assuming early efficacy data would be enough for accelerated approval
- Others changed dosage forms mid-study without a bridging plan.
In both cases, the outcome was the same: Costly delays, regulatory setbacks, and investor frustration.
By contrast, teams that invested early in strategy, defining their TPP, aligning stakeholders, and engaging regulators, navigated challenges faster and kept development on track.
5. A Living Strategy
A Dynamic Regulatory Strategy for Product Development is Essential
Markets shift. Competitors emerge. Regulations evolve.
A static plan won’t survive dynamic environments. A living regulatory strategy reviewed regularly and informed by new data keeps your program aligned and adaptive.
Whether your goal is commercialisation, partnership, or exit, your strategy should guide every decision: clinical design, manufacturing standards, and market access planning.
Key
Takeaways
Success isn’t just about innovation, it’s about disciplined execution. Early regulatory planning can accelerate timelines, lower costs, and ensures compliance.
- Incorporating the TPP into early regulatory planning bridges the gap between scientific discovery and real-world product approval.
- If you’re developing a new medicine or device, don’t treat regulatory strategy as a box to tick. Build it in from day one.
- Engage experts.
- Define your TPP.
- Embed quality.
- Stay flexible.
At The Adjutor Group, we are committed to supporting you every step of the way.
Frequently Asked Questions
Regulatory strategy is the plan that defines how a drug or medical device will move from development to regulatory approval. It aligns the Target Product Profile, clinical evidence, quality systems, and regulatory pathways so that development decisions support approval, commercialisation, and investor confidence.
Regulatory planning should begin before or at the very start of development. Early strategy prevents misclassification, inappropriate clinical studies, quality system gaps, and costly delays that often occur when regulatory considerations are added later.
A Target Product Profile (TPP) defines what the final approved product must look like from a clinical, regulatory, and commercial perspective. It guides study design, regulatory interactions, and investment decisions, ensuring development stays aligned with approval requirements.
Medicines are regulated primarily through clinical evidence of safety and efficacy, while medical devices follow risk-based classification and performance requirements. Regulatory strategy must account for these differences as well as variations between regions such as TGA, FDA, and European authorities.
Quality systems such as GLP, GCP, GMP, ISO 13485, ISO 14971 and risk management must be embedded early to avoid clinical holds, manufacturing failures, and compliance gaps. Retrofitting quality later often leads to major delays and regulatory setbacks.
Regulatory strategy is the plan that defines how a drug or medical device will move from development to regulatory approval. It aligns the Target Product Profile, clinical evidence, quality systems, and regulatory pathways so that development decisions support approval, commercialisation, and investor confidence.
Choosing the Right Regulatory Affairs Consultant.
Further reading:
Featured Post
How to Register a Medicine in Australia
Six ways to register a medicine in Australia: Understanding the complexities of medicine registration […]
June 28, 2024
·
Featured Post
Medical Device Registration in Australia
Key considerations in navigating the regulatory process to register a medical device in Australia […]
July 19, 2024
·
At The Adjutor Group, we don’t just file submissions, we design regulatory pathways to suit your unique requirements. Contact us for a confidential discussion and customised proposal for your next project and get the Adjutor Advantage working for you today!
- TPP regulatory strategy
- Market access alignment
- Investment readiness
- FDA and TGA strategic regulatory consulting
- Global regulatory pathways
- Full service Clinical Research Organisation (CRO)
How should we plan regulatory strategy for a new drug or device?
Learn why regulatory strategy for drug and device development should be your first step. Get expert insights from Adjutor to save time, reduce cost and ensure approval.
